EBE is the voice of biopharma in Europe, bringing together innovators and developers of biopharmaceuticals of all sizes (small, mid-size and large).
Our mission, as the only European industry association fully dedicated to healthcare biotech, is that we are the source of expertise on emerging science and biopharma innovation in Europe.
Our work topics are geared to fulfill this mission. They include bio-manufacturing, bio-therapeutics, advanced therapies, personalised medicines including novel & combination therapies, allergen immunotherapy and medicines based on or working through the microbiome.
A key focus of EBE is to work on funding and innovation models for innovative companies and small and medium-sized enterprises (SMEs). Our goal is to improve the funding options available in Europe to ensure that innovative SMEs in research-intensive areas like biopharmaceuticals find the right conditions in Europe to develop into successful businesses, brining new job opportunities to the European economy.
We create added value for members through working groups that develop clear policy positions, access to expertise, to regulators and legislators, and through representing the interests of innovative developers of biopharmaceuticals.
We provide services to our members through knowledge sharing, including dedicated training and information sharing sessions, access to content, regulatory know-how and science & market intelligence.
In part this knowledge is shared at our regular working group meetings, and specific topical meetings, such as our exchange with two Members of the European Parliament on biosimilars and other issues related to medicines that are currently under discussion.
EBE, being a specialised group of EFPIA, our members also profit from access to the Innovative Medicines Initiative (IMI), the largest public-private-partnership dedicated to the development of innovative medicines, and to EFPIA work topics.